Viropro Inc. (VPRO) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 3.61: the stock has moved about 261% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerViropro Inc. (VPRO) trades at $0.00002. Viropro Inc. is a biotechnology company specializing in the contract research, development, and manufacture of biotherapeutic proteins. Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for VPRO: VPRO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Viropro Inc. (VPRO) Healthcare & Pipeline Overview
Viropro Inc. operates in the biotechnology sector, focusing on the contract research and development of biotherapeutic proteins, positioning itself as a key player in the production of biosimilars and biogeneric therapeutic solutions.
What Is the Investment Thesis for VPRO?
Viropro Inc. presents a unique investment thesis driven by its strong position in the biotechnology sector and its focus on biotherapeutic proteins. The company's gross margin stands at an impressive 100%, indicating effective cost management and operational efficiency. Key growth catalysts include its ongoing collaboration with Oncobiologics, which may enhance its product offerings and market reach. Additionally, the increasing global demand for biosimilars and biogeneric drugs, projected to grow significantly in the coming years, positions Viropro to capitalize on this trend. However, the company faces risks, including a high profit margin of -176.9%, indicating potential financial instability. Investors may want to evaluate these metrics and the competitive landscape as they evaluate Viropro's potential for growth and profitability.
Based on FMP financials and quantitative analysis
VPRO Key Highlights
Gross margin of 100.0% reflects high operational efficiency in the biotechnology sector.
- Profit margin of -176.9% indicates significant financial challenges that need to be addressed.
- Market Cap is currently at $0.00B, suggesting low market valuation or trading activity.
- Beta of 3.61 indicates high volatility compared to the market, which may affect investor sentiment.
- No dividend yield, reflecting a focus on reinvestment rather than returning capital to shareholders.
Who Are VPRO's Competitors?
VPRO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals, Inc. | $735.20 | +0.05% | $75.7B | 94 5-pillar |
| AMGN Amgen Inc. | $403.04 | -1.04% | $218B | 85 5-pillar |
| BMY Bristol-Myers Squibb Company | $61.15 | -0.50% | $125B | 91 5-pillar |
| SNY Sanofi | $39.92 | -1.84% | $95.9B | 83 5-pillar |
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | — |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | — |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | — |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VPRO's Key Strengths?
Strong gross margin indicating operational efficiency.
- Expertise in biotherapeutic protein development.
- Established collaborations with industry players.
- Diverse product offerings across multiple therapeutic areas.
What Are VPRO's Weaknesses?
Negative profit margin indicating financial challenges.
- Low market capitalization suggesting limited investor interest.
- High beta indicating volatility and risk.
- Lack of dividend payments may deter income-focused investors.
What Are the Key Risks for VPRO?
Financial-distress signal — its Altman Z-Score of -0.92 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Financial instability indicated by a negative profit margin.
- Regulatory challenges that could delay product approvals.
- High volatility in stock price due to low market capitalization.
- Competition from larger biotech firms with more resources.
What Threats Does VPRO Face?
- Intense competition in the biotechnology sector.
- Regulatory challenges in drug development and approval.
- Market volatility affecting investor confidence.
- Rapid technological changes requiring continuous innovation.
What Are VPRO's Competitive Advantages?
- Strong expertise in biotherapeutic protein development.
- Proprietary technologies for efficient biomanufacturing.
- Established relationships with key players in the biotech industry.
- Diverse product offerings catering to various therapeutic areas.
- International operations providing a competitive edge in global markets.
What Does VPRO Do?
Founded in San Jose, California, Viropro Inc. has established itself as a significant player in the biotechnology industry, primarily through its subsidiaries. The company is engaged in the contract research, development, and manufacture of biotherapeutic proteins aimed at treating a variety of diseases, including cancer, diabetes, hepatitis, and multiple sclerosis. Over the years, Viropro has evolved by not only developing its proprietary technologies for the industrial production of biogeneric therapeutic proteins but also by offering comprehensive services to biotech and biopharmaceutical companies. Its product offerings include biologics drugs, biosimilars for pre-clinical and clinical trials, and mammalian cell proteins such as monoclonal antibodies and recombinant proteins. Viropro also possesses three proprietary clones, two of which are focused on insulin therapy and one on cancer therapy. The company operates internationally, with facilities and operations in Canada, the United Kingdom, and Malaysia. Viropro has also formed a collaboration agreement with Oncobiologics, Inc. to manufacture and commercialize monoclonal antibody products, further enhancing its market presence and capabilities. As a subsidiary of Alpha Biologics Limited, Viropro Inc. continues to pursue innovative solutions in biotherapeutics, addressing critical healthcare challenges.
What Products and Services Does VPRO Offer?
- Engage in contract research and development of biotherapeutic proteins.
- Manufacture biogeneric therapeutic proteins for various diseases.
- Provide services for pre-clinical and clinical trials.
- Supply mammalian cell proteins, including monoclonal antibodies.
- Own proprietary clones for insulin and cancer therapies.
- Collaborate with other biotech firms for product commercialization.
How Does VPRO Make Money?
- Generate revenue through contract research and manufacturing services.
- Develop and sell biotherapeutic proteins and biosimilars.
- Engage in partnerships for the commercialization of biopharmaceutical products.
- Utilize proprietary technologies for efficient production.
- Focus on international markets to expand customer base.
What Industry Does VPRO Operate In?
The biotechnology industry is experiencing robust growth, driven by advancements in biotherapeutics and an increasing demand for innovative treatments. The global biosimilars market is projected to expand significantly, with estimates suggesting a CAGR of over 30% in the coming years. Viropro Inc. fits into this competitive landscape by providing contract research and manufacturing services, catering to a growing number of biotech firms looking to develop biosimilars and biogeneric drugs. As the industry evolves, companies like Viropro that specialize in biotherapeutics are poised to benefit from increased investment and collaboration opportunities.
Who Are VPRO's Key Customers?
- Biotech companies seeking contract research and manufacturing services.
- Pharmaceutical companies looking for biosimilar development.
- Healthcare providers needing innovative therapeutic solutions.
- Research institutions conducting clinical trials.
- International clients in need of biotherapeutic proteins.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Key Financial Metrics
Return on assets is -47.8%, showing how much profit it generates from its asset base. A current ratio of 0.26 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Viropro Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Jose, United States.
Financial Health
Viropro Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.92 places it in the distress zone, a signal of elevated financial risk.
VPRO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
VPRO Latest News
No recent news available for VPRO.
VPRO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for VPRO.
Price Targets
Wall Street price target analysis for VPRO.
VPRO MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for VPRO; grades run from A+ (80-100) to F (below 30).
Leadership: Michelle Leanne Edythe Peake
CEO
Michelle Leanne Edythe Peake has a robust background in biotechnology and pharmaceutical management, with over 15 years of experience in the industry. She holds a degree in Biotechnology from a leading university and has held various leadership roles in both startups and established firms. Her expertise lies in bioprocessing and biopharmaceutical development, making her well-suited to lead Viropro Inc. in its strategic initiatives.
Track Record: Under Michelle's leadership, Viropro has established key partnerships and expanded its product offerings. She has successfully navigated the company through challenging market conditions while focusing on innovation and operational efficiency.
VPRO OTC Market Information
The OTC Other tier is a classification for companies that do not meet the requirements for higher-tier OTC markets or major exchanges like NYSE or NASDAQ. This tier often includes smaller companies with lower trading volumes and less stringent reporting requirements, which can lead to higher risks.
- OTC Tier: OTC Other
- Limited financial reporting can obscure the company's financial health.
- Low trading volume may lead to price volatility and liquidity issues.
- Regulatory scrutiny can impact operations and market perception.
- Potential lack of investor interest can affect stock performance.
- Verify the company's financial health and operational metrics.
- Assess the competitive landscape and market positioning.
- Review any existing collaborations and their potential impact.
- Evaluate the management team's experience and track record.
- Monitor industry trends and regulatory changes affecting the sector.
- Established partnerships with recognized companies in the biotech sector.
- Presence in multiple international markets indicates operational credibility.
- Strong focus on innovation and development of biotherapeutics.
What Investors Ask About Viropro Inc. (VPRO) — Healthcare
What are the main risks for VPRO?
Viropro Inc. faces several risks, including financial instability reflected in its negative profit margin. Regulatory challenges could impact the approval of its products, while high volatility in its stock price, due to low market capitalization, poses additional risks. Furthermore, competition from larger biotech firms could hinder its market share and growth potential.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited financial data available for comprehensive analysis